Lobbying disclosures · Lobbying report
ABBV: second_quarter 2026 lobbying report
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical su
Follow ABBV- Became public
- Oct 19, 2026, 12:05 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 9:38 AM EST
Why this is connected
Exact legal-name match: AbbVie Inc. (https://www.sec.gov/Archives/edgar/data/1551152/).
Reported lobbying amounts
Income: $90,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/153291fc-bbdb-4543-b39e-af667faaca37/","filing_uuid":"153291fc-bbdb-4543-b39e-af667faaca37","filing_type":"2A","filing_type_display":"2nd Quarter - Amendment","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/153291fc-bbdb-4543-b39e-af667faaca37/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Isabella Quinn","dt_posted":"2026-10-19T12:05:37-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 Pennsylvania Avenue, NW","registrant_address_2":"Suite 800","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":41454,"url":"https://lda.gov/api/v1/registrants/41454/","house_registrant_id":30771,"name":"WILLIAMS AND JENSEN, PLLC","description":"Lobbying Law Firm","address_1":"1201 Pennsylvania Avenue, NW","address_2":"Suite 800","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ISABELLA QUINN","contact_telephone":"+1 202-659-8201","dt_updated":"2026-07-30T10:41:36.640087-04:00"},"client":{"id":71889,"url":"https://lda.gov/api/v1/clients/71889/","client_id":71889,"name":"ABBVIE, INC.","general_description":"Biopharmaceutical company","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-03-20"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141323,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"ZIEGLER","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson","new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false},{"lobbyist":{"id":69840,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":"E.","last_name":"WILCOX","suffix":null,"suffix_display":null},"covered_position":"LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141323,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"ZIEGLER","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson","new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false},{"lobbyist":{"id":69840,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":"E.","last_name":"WILCOX","suffix":null,"suffix_display":null},"covered_position":"LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings","new":false},{"lobbyist":{"id":43332,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":"W","last_name":"HATCHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141323,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"ZIEGLER","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson","new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false},{"lobbyist":{"id":69840,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":"E.","last_name":"WILCOX","suffix":null,"suffix_display":null},"covered_position":"LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":14682,"prefix":null,"prefix_display":null,"first_name":"SUSAN","nickname":null,"middle_name":null,"last_name":"HIRSCHMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141323,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"ZIEGLER","suffix":null,"suffix_display":null},"covered_position":"Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson","new":false},{"lobbyist":{"id":144121,"prefix":null,"prefix_display":null,"first_name":"JEANNE","nickname":null,"middle_name":null,"last_name":"HAGGERTY","suffix":null,"suffix_display":null},"covered_position":"Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member","new":false},{"lobbyist":{"id":149999,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":null,"last_name":"BUTORA","suffix":null,"suffix_display":null},"covered_position":"Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess","new":false},{"lobbyist":{"id":69840,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":"E.","last_name":"WILCOX","suffix":null,"suffix_display":null},"covered_position":"LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
+0.37% ABBV
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in ABBV
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Sep 18, 2026$15K–$50K
Rep. Pete Sessions (R-TX-17)
$15K–$50K · Traded Sep 14, 2026 · disclosed Sep 18, 2026
- Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 3, 2026$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
$1K–$15K · Traded May 5, 2026 · disclosed Jun 3, 2026 · Joint
- Feb 6, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 15, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Dec 18, 2025 · disclosed Jan 15, 2026 · Joint
- Jan 13, 2026$1K–$15K
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.